News | December 04, 2013

Mammography Screening Intervals May Affect Breast Cancer Prognosis

ct systems imaging women's healthcare rsna 2013 mammography systems

Patient 1: Bilateral MLO views from screening mammography in a 53-year-old woman.

ct systems imaging women's healthcare rsna 2013 mammography systems

Spot magnification view demonstrates an irregular spiculated mass with associated calcifications in the upper outer left breast. Ultrasound biopsy revealed invasive ductal carcinoma and DCIS.

ct systems imaging women's healthcare rsna 2013 mammography systems

Bilateral MLO views.

ct systems imaging women's healthcare rsna 2013 mammography systems

Patient 2: Screening mammogram in a 63-year-old woman demonstrated calcifications in the upper outer left breast. Bilateral CC views shown here.

ct systems imaging women's healthcare rsna 2013 mammography systems

Spot magnification view demonstrates suspicious linear branching calcifications. Stereotactic biopsy revealed DCIS.

ct systems imaging women's healthcare rsna 2013 mammography systems

Patient 3: Screening mammogram in a 61-year-old woman demonstrates architectural distortion in the upper outer left breast.

ct systems imaging women's healthcare rsna 2013 mammography systems

Bilateral MLO views. Ultrasound biopsy demonstrated invasive mammary carcinoma and DCIS.

December 4, 2013 — In a study of screening mammography-detected breast cancers, patients who had more frequent screening mammography had a significantly lower rate of lymph node positivity — or cancer cells in the lymph nodes — as compared to women who went longer intervals between screening mammography exams. Results of the study were presented at the Radiological Society of North America Annual Meeting (RSNA 2013).
 
In its earliest stages, breast cancer is confined to the breast and can be treated by surgically removing the cancer cells. As the disease progresses, breast cancer cells may spread to the lymph nodes and then to other areas of the body.
 
"On its pathway to other places in the body, the first place breast cancer typically drains into before metastasizing is the lymph nodes," said Lilian Wang, M.D., assistant professor of radiology, Northwestern University/Feinberg School of Medicine in Chicago. "When breast cancer has spread into the lymph nodes, the patient is often treated both locally and systemically, with either hormone therapy, chemotherapy, trastuzumab or some combination of these therapies."
 
Historically, healthcare organizations, such as RSNA and the American Cancer Society (ACS), have recommended annual screening with mammography for women beginning at age 40. However, in 2009, the United States Preventive Services Task Force (USPSTF) announced a controversial new recommendation for biennial screening for women between the ages of 50 and 74.
 
"Our study looks at what would happen if the revised guidelines issued by USPSTF were followed by women," said Wang.
 
The retrospective study, conducted at Northwestern Memorial Hospital, included 332 women with breast cancer identified by screening mammography between 2007 and 2010. The women were divided into one of three groups based on the length of time between their screening mammography exams: less than 1.5 years, 1.5 to 3 years and more than 3 years. There were 207, 73 and 52 patients in each category, respectively. Controlling for age, breast density, high-risk status and a family history of breast cancer, the researchers determined that women in the less than 1.5-year interval group had the lowest lymph node positivity rate at 8.7 percent. The rate of lymph node involvement was significantly higher in the 1.5- to three-year and over three-year interval groups at 20.5 percent and 15.4 percent, respectively.
 
"Our study shows that screening mammography performed at an interval of less than 1.5 years reduces the rate of lymph node positivity, thereby improving patient prognosis," said Wang. "We should be following the guidelines of the American Cancer Society and other organizations, recommending that women undergo annual screening mammography beginning at age 40."
 
Co-authors are Ellen Mendelson, M.D., Paula Grabler, M.D., Riti Mahadevia, B.A., and Laura Billadello, M.D.
 
For more information: www.rsna.org

Related Content

FDA Approves New Features for Planmed Verity Cone Beam CT Scanner
Technology | Computed Tomography (CT) | December 07, 2018
The U.S. Food and Drug Administration (FDA) issued an approval letter for the new features and intended uses of the...
FDA Clears iCAD's ProFound AI for Digital Breast Tomosynthesis
Technology | Mammography | December 07, 2018
iCAD Inc. announced clearance by the U.S. Food and Drug Administration (FDA) for their latest, deep-learning, cancer...
YITU Releases AI-Based Cancer Screening Solutions at RSNA 2018
News | Artificial Intelligence | December 06, 2018
Chinese artificial intelligence (AI) healthcare company YITU healthcare released two brand-new products, Intelligent...
Guerbet Launches Multi-Use OptiVantage Contrast Media Injector in Europe
Technology | Contrast Media Injectors | December 05, 2018
Contrast agent company Guerbet recently announced that the OptiVantage multi-use contrast media injector is now CE...
GE Healthcare Unveils New Applications and Smart Devices Built on Edison Platform
Technology | Artificial Intelligence | December 05, 2018
GE Healthcare recently announced new applications and smart devices built on Edison – a platform that helps accelerate...
Fujifilm Collaborates With Lunit on AI Pilot Project
News | Artificial Intelligence | December 05, 2018
Fujifilm Medical Systems USA Inc. announced a joint collaboration with Korean-based medical artificial intelligence (AI...
ScreenPoint Medical and Volpara Partner to Bring AI to Breast Imaging Clinics
News | Computer-Aided Detection Software | December 04, 2018
ScreenPoint Medical has signed a memorandum of understanding (MOU) with Volpara Health Technologies. Volpara will...
GE Healthcare Introduces Invenia ABUS 2.0
Technology | Ultrasound Women's Health | December 03, 2018
GE Healthcare recently launched the Invenia automated breast ultrasound (ABUS) 2.0 system in the United States. This...
Infervision Introduces AI Capabilities for Chest CT Reading
Technology | Computer-Aided Detection Software | November 30, 2018
Big data and artificial intelligence (AI) company Infervision announced the launch of InferRead CT Chest, a new product...
NeuroLogica and MaxQ AI Announce Distribution Agreement
News | Stroke | November 30, 2018
Clinical diagnostics intelligence platform company MaxQ AI and Samsung NeuroLogica announced a distribution agreement...